Cialis (Tadalafil) and Simvastatin Interaction: Safety, Risks, and Clinical Guidance

Updated May 26, 2026

Image: HealthRX.com clinical image

This article is a draft pending qualified clinical review. It is educational and does not replace individualized advice from a prescriber or pharmacist who knows your full medication list and health history.

Tadalafil is the generic name for the PDE5 (phosphodiesterase type 5) inhibitor sold as Cialis, approved for erectile dysfunction and, at lower daily doses, for benign prostatic hyperplasia. Simvastatin is a statin (HMG-CoA reductase inhibitor) sold as Zocor, used to lower LDL cholesterol. Both drugs are metabolized in part through the liver enzyme CYP3A4, which is why patients and clinicians reasonably ask whether combining them is safe.

Tadalafil and simvastatin do not have a documented direct pharmacokinetic interaction with each other according to current FDA labeling for either drug. Both are CYP3A4 substrates, but being metabolized by an enzyme is not the same as inhibiting it, and tadalafil is not listed as a CYP3A4 inhibitor in its FDA label. The clinically important scenario is not this pair alone but what happens when a third drug that is a genuine strong or moderate CYP3A4 inhibitor is added to a regimen that already includes simvastatin. That is where simvastatin's dose caps and contraindications become relevant, independent of whether tadalafil is present.

The direct answer, with its boundary

Simvastatin's FDA label restricts co-administration with strong CYP3A4 inhibitors (drugs such as itraconazole, ketoconazole, clarithromycin, and certain HIV protease inhibitors) and caps the dose at 20 mg per day when a moderate CYP3A4 inhibitor is used, because these combinations raise simvastatin exposure and increase myopathy and rhabdomyolysis risk (accessdata.fda.gov, Zocor label). Tadalafil is not classified in FDA labeling as a CYP3A4 inhibitor at approved doses, and the tadalafil label states it is "not expected to cause clinically significant inhibition or induction" of CYP-mediated drug clearance (accessdata.fda.gov, Cialis label). Taken together, these two label statements support the conclusion that tadalafil does not meaningfully raise simvastatin levels through this pathway, though a dedicated tadalafil-simvastatin pharmacokinetic study confirming the magnitude of any residual effect should be checked in the primary literature before treating this as a fully quantified interaction.

CYP3A4 metabolizes a large share of prescription drugs. When two CYP3A4 substrates are combined, there is a theoretical concern that they compete for the enzyme and raise each other's blood levels. In practice, the risk depends heavily on whether either drug also inhibits the enzyme, not merely whether it is metabolized by it.

Simvastatin's label groups CYP3A4-interacting drugs into inhibitor categories (strong, moderate) because inhibitors block simvastatin's clearance and let it accumulate. Tadalafil does not appear in that inhibitor list. This is the key distinction: tadalafil is a substrate without inhibitor activity at labeled doses, which is a materially different risk profile than adding a drug like clarithromycin or a protease inhibitor.

What is established, what is plausible, and what still needs verification

Evidence-status assessment for tadalafil + simvastatin

Claim	Status	Basis
Tadalafil and simvastatin are both CYP3A4 substrates	Established	FDA labels for both drugs
Tadalafil is not a clinically significant CYP3A4 inhibitor at approved doses	Established	FDA tadalafil label statement
Simvastatin requires dose caps or avoidance with strong/moderate CYP3A4 inhibitors	Established	FDA simvastatin label
Tadalafil meaningfully raises simvastatin plasma levels	Not established as a labeled interaction	No FDA label warning for this specific pair; a dedicated pharmacokinetic study should be checked before quoting a specific percentage change
Combining tadalafil and simvastatin adds any incremental rhabdomyolysis risk beyond simvastatin's baseline risk	Not established	No signal identified in FDA labeling; absence of a documented signal is not proof of zero risk in all patients
Statins improve erectile function scores via endothelial/nitric oxide effects	Plausible mechanism, described in the sexual medicine literature	Requires verification of the specific trial(s) before citing an effect size; mechanism (endothelial function, nitric oxide) is biologically coherent but the magnitude claimed in earlier drafts of this topic could not be confirmed from the sources on hand
Grapefruit juice raises simvastatin exposure through intestinal CYP3A4 inhibition	Established general pharmacology, direction of effect	FDA simvastatin label warns against grapefruit juice; exact fold-increase figures vary by study design and should be sourced to a specific trial before quoting a number
Blood pressure effects of tadalafil and simvastatin are additive in a clinically meaningful way for most patients	Not established as a general rule	Each drug has a documented but small mean blood pressure effect in its own trials; additive risk in combination has not been separately quantified in the sources reviewed here
Third-drug CYP3A4 inhibition (clarithromycin, itraconazole, protease inhibitors, amiodarone, diltiazem, verapamil) meaningfully changes the safety picture for simvastatin	Established	FDA simvastatin label dose-adjustment and contraindication tables

What a clinician or pharmacist should verify before finalizing guidance for an individual patient: the patient's full CYP3A4-relevant medication list (not just tadalafil), current simvastatin dose, renal function if tadalafil dosing needs adjustment, and any personal or family history of statin-associated myopathy.

When this combination becomes a real safety concern

The scenario that actually changes risk is the addition of a third drug that strongly or moderately inhibits CYP3A4 to a regimen that already includes simvastatin. Tadalafil being present does not change this calculus one way or the other, based on current labeling. Examples drawn directly from the simvastatin label's own restrictions include:

Starting a macrolide antibiotic such as clarithromycin while on simvastatin: the label directs avoiding or interrupting simvastatin during treatment.
Starting an azole antifungal such as itraconazole or ketoconazole: simvastatin is contraindicated during concurrent use.
Starting diltiazem, verapamil, or amiodarone: simvastatin dose is capped at 20 mg per day per FDA labeling.
Starting a boosted HIV protease inhibitor: simvastatin is contraindicated regardless of any other drug in the regimen.

None of these restrictions are altered by whether the patient is also taking tadalafil. A clinician reviewing this combination should focus attention on the rest of the medication list rather than on the tadalafil-simvastatin pair itself.

Statins and erectile function: mechanism versus evidence quality

There is a biologically plausible reason statins and PDE5 inhibitors might have complementary rather than opposing effects: statins are thought to improve endothelial function and nitric oxide availability, which is the same signaling pathway tadalafil acts downstream of by preserving cyclic GMP. This mechanistic overlap has been proposed in the sexual medicine literature. However, an earlier version of this article cited a specific meta-analysis and effect size for statin-related improvement in erectile function scores that could not be verified against a confirmed primary source in this review. Readers and clinicians should treat any specific numeric claim about statins improving erectile function scores as unconfirmed until checked against the original trial or meta-analysis, rather than relying on a number quoted secondhand.

Monitoring that actually matters for this combination

No FDA-mandated laboratory monitoring is specific to the tadalafil-simvastatin combination itself. Standard, individually-indicated monitoring still applies:

Lipid panel: baseline and periodic follow-up per the prescriber's statin monitoring plan.
Liver enzymes: routine monitoring is no longer required by FDA for statins generally, though a baseline check before starting simvastatin remains common practice; this should be confirmed with the prescriber rather than assumed.
Creatine kinase (CK): current guidance from cholesterol management bodies generally favors symptom-triggered CK testing over routine testing in patients without symptoms. Muscle pain, tenderness, weakness, or dark urine warrants prompt evaluation and possible CK testing, not routine screening in an asymptomatic patient.
Renal function: relevant to tadalafil dosing, since the tadalafil label recommends lower starting and maximum doses in patients with significant renal impairment. This is a tadalafil-specific consideration independent of simvastatin.

Patients on this combination should be told to seek prompt medical attention for unexplained muscle pain or weakness, dark or tea-colored urine, or an erection lasting longer than four hours, the last being a urologic emergency unrelated to the statin interaction question.

Grapefruit juice: a caveat that applies to simvastatin regardless of tadalafil

Grapefruit juice inhibits intestinal CYP3A4 and is addressed directly in simvastatin's FDA labeling as something to avoid or limit. The direction of this effect is well established; the exact magnitude reported varies across studies and dosing conditions, so a specific fold-increase figure should be sourced to a named study before being repeated as a fixed number. The practical guidance that follows from the label is straightforward: patients on simvastatin should avoid or strictly limit grapefruit juice. This applies whether or not tadalafil is also being taken. Tadalafil's own label does not carry a specific grapefruit contraindication, though a modest exposure increase is plausible given the shared CYP3A4 pathway.

Timing and administration

Simvastatin is commonly dosed in the evening because hepatic cholesterol synthesis is higher overnight, though this timing preference is a practice convention rather than a strict FDA requirement for all patients. Tadalafil is dosed either as-needed before sexual activity or as a lower daily dose for ED or BPH, per its FDA label. Because tadalafil does not act as a CYP3A4 inhibitor, there is no pharmacokinetic reason documented in either drug's label to separate the timing of the two medications. Patients can generally coordinate dosing around convenience and adherence, but should confirm this with their prescriber, particularly if either drug's dose is at the higher end of its labeled range.

What is genuinely uncertain here

This page can support the statement that tadalafil and simvastatin do not have a labeled direct interaction, and that the real risk driver is any third CYP3A4-inhibiting drug added to simvastatin. It cannot support precise numeric claims about how much tadalafil might shift simvastatin exposure, precise incidence rates of rhabdomyolysis with this specific pairing, or a quantified erectile-function benefit from statins, because the underlying studies for those numbers were not confirmed as accurate primary sources during this review. Where a number is needed for an individual clinical decision, it should come from the current FDA label or a verified primary study, not from this article.

Frequently asked questions

Can I take Cialis with simvastatin?

Based on current FDA labeling, tadalafil is not classified as a CYP3A4 inhibitor, and simvastatin's label does not list tadalafil among drugs requiring a dose adjustment. There is no documented direct interaction requiring a dose change for either drug on this basis alone. This does not account for other medications you may be taking, which should be reviewed by your prescriber or pharmacist.

Does tadalafil raise simvastatin blood levels?

Tadalafil is not listed as a CYP3A4 inhibitor in its FDA label, which is the mechanism that would be expected to raise simvastatin levels. A dedicated pharmacokinetic study quantifying any small residual effect was not confirmed as part of this review, so an exact percentage should not be treated as established.

What actually raises rhabdomyolysis risk when someone is on simvastatin?

The simvastatin FDA label identifies strong and moderate CYP3A4 inhibitors, such as certain antibiotics, antifungals, and antiarrhythmics, along with high simvastatin doses, as the drivers of increased myopathy and rhabdomyolysis risk. Tadalafil is not among the drugs listed in that label as requiring a simvastatin dose adjustment.

Should I separate the timing of tadalafil and simvastatin?

Neither drug's FDA label specifies a required timing separation from the other. Because tadalafil is not a CYP3A4 inhibitor, there is no pharmacokinetic rationale in the labeling for spacing the doses apart, though individual prescriber guidance should take priority.

What symptoms should prompt me to stop simvastatin and call my doctor?

Unexplained muscle pain, tenderness, or weakness, and dark or tea-colored urine, warrant prompt contact with your prescriber and possible creatine kinase testing. These are general statin safety signs, not specific to combining simvastatin with tadalafil.

Can I drink grapefruit juice while taking simvastatin?

Simvastatin's FDA label advises against or limits grapefruit juice because it inhibits intestinal CYP3A4 and can raise simvastatin levels. This applies regardless of whether tadalafil is also being taken.

References

U.S. Food and Drug Administration. Cialis (tadalafil) prescribing information, accessdata.fda.gov drug label database.
U.S. Food and Drug Administration. Zocor (simvastatin) prescribing information, accessdata.fda.gov drug label database.

Delivery note for editorial and clinical review: the original draft of this article contained a named physician quotation, a specific meta-analysis effect size for statins and erectile function, and several precise pharmacokinetic percentages (fold-increases, IC50 values, incidence rates) that could not be verified against a confirmed primary source during this pass. These were removed or converted to general, appropriately hedged statements rather than retained as unverified precise figures. A qualified reviewer with access to the primary literature should confirm whether any of these specific numbers can be restored with a correct citation.